Molecular cytogenetic analysis of chromosome 8 aberrations in patients with multiple myeloma examined in 2 different stages, at diagnosis and at progression/relapse

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F16%3AN0000021" target="_blank" >RIV/00098892:_____/16:N0000021 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00090553 RIV/61989592:15110/16:33159335

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Molecular cytogenetic analysis of chromosome 8 aberrations in patients with multiple myeloma examined in 2 different stages, at diagnosis and at progression/relapse

Popis výsledku v původním jazyce

This retrospective study of 62 patients with multiple myeloma examined at 2 different phases (diagnosis and progression/relapse), revealed chromosome 8 aberrations in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. We did not confirm a significant increase of chromosome 8 aberrations at progression/relapse; however, we confirmed the heterogeneity of the aberrations and their poor prognostic impact on overall survival. Background: The genome of multiple myeloma (MM) clonal plasma cells is characterized by genetic changes of prognostic importance. Disease progression is accompanied by a number of secondary chromosomal aberrations including chromosome 8. We focused on the detection of chromosome 8 aberrations in patients with MM who were examined at 2 different phases: diagnosis and progression/relapse. Patients and Methods: A total of 62 patients with MM were examined at the time of diagnosis and at relapse/progression. The median age was 64 years (range, 39-78 years); the study included 29 males and 33 females. We analyzed bone marrow samples for detecting aberrations on chromosome 8 by the fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) and fluorescence in situ hybridization methods with specific probes. Results: Chromosome 8 aberrations were detected in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. Only 5 (8%) patients developed additional chromosome 8 changes at progression/relapse. The aberrations were heterogeneous, involving numerical and structural changes of the MYC gene. Aberrations of the short arm of chromosome 8, involving the genes TRAIL-R1/-R2, were less frequent (4 of 62 patients, 6.4%). All aberrations of chromosome 8 were accompanied with additional changes and with an advanced clinical phase of the disease. This finding significantly influenced the overall survival of patients.

Název v anglickém jazyce

Molecular cytogenetic analysis of chromosome 8 aberrations in patients with multiple myeloma examined in 2 different stages, at diagnosis and at progression/relapse

Popis výsledku anglicky

This retrospective study of 62 patients with multiple myeloma examined at 2 different phases (diagnosis and progression/relapse), revealed chromosome 8 aberrations in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. We did not confirm a significant increase of chromosome 8 aberrations at progression/relapse; however, we confirmed the heterogeneity of the aberrations and their poor prognostic impact on overall survival. Background: The genome of multiple myeloma (MM) clonal plasma cells is characterized by genetic changes of prognostic importance. Disease progression is accompanied by a number of secondary chromosomal aberrations including chromosome 8. We focused on the detection of chromosome 8 aberrations in patients with MM who were examined at 2 different phases: diagnosis and progression/relapse. Patients and Methods: A total of 62 patients with MM were examined at the time of diagnosis and at relapse/progression. The median age was 64 years (range, 39-78 years); the study included 29 males and 33 females. We analyzed bone marrow samples for detecting aberrations on chromosome 8 by the fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) and fluorescence in situ hybridization methods with specific probes. Results: Chromosome 8 aberrations were detected in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. Only 5 (8%) patients developed additional chromosome 8 changes at progression/relapse. The aberrations were heterogeneous, involving numerical and structural changes of the MYC gene. Aberrations of the short arm of chromosome 8, involving the genes TRAIL-R1/-R2, were less frequent (4 of 62 patients, 6.4%). All aberrations of chromosome 8 were accompanied with additional changes and with an advanced clinical phase of the disease. This finding significantly influenced the overall survival of patients.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT14400" target="_blank" >NT14400: Studium úlohy genových a chromozomových aberací v rámci maligní transformace MGUS a v průběhu mnohočetného myelomu - využití poznatků pro diagnostiku a stratifikaci v klinické praxi</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Lymphoma, Myeloma & Leukemia

ISSN

2152-2650

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

358-365

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—